Clinical trials
Colorectal Cancer (Locally Advanced or Metastatic) clinical trials
Below are recruiting colorectal cancer (locally advanced or metastatic) clinical trials, each written for real people, not researchers. We’re tracking 5,557 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07395804Recruiting
How darolutamide works for advanced prostate cancer in Germany
This study looks at how well a drug called darolutamide (a type of hormone therapy) works in everyday medical practice for men with advanced prostate cancer that has spread. It is for men who are already starting this treatment with their doctor and will help doctors understand how it works in real life.
LocationsAges 18 years+ - NCT07392346RecruitingPhase 2
Fruquintinib combo for advanced gastric cancer after immunotherapy
This trial tests a combination of targeted therapy (fruquintinib), chemotherapy (nab-paclitaxel), and two immunotherapies (iparomlimab and tuvonralimab) for people with advanced stomach or gastroesophageal junction cancer whose first treatment with a PD-1/PD-L1 inhibitor stopped working. The goal is to see if this new combination can shrink tumors and improve outcomes.
Beijing, Beijing MunicipalityAges 18 years+ - NCT07386704Enrolling by invitationPhase 2
Nimotuzumab with chemo and radiation for advanced pancreatic cancer
This trial tests adding nimotuzumab (a targeted antibody) to standard chemoradiation for people with advanced pancreatic cancer that cannot be removed by surgery. The goal is to see if this combination can shrink tumors or slow their growth.
Beijing, Beijing MunicipalityAges 18–80 - NCT05889247Recruiting
Blood test guided monitoring for advanced lung cancer treatment
This trial checks whether a blood test that looks for cancer DNA can help guide and monitor treatment in people with advanced non-small cell lung cancer (NSCLC). It may help your team spot treatment response or changes earlier, so care can be adjusted appropriately.
Hillerød, Region HAges Any age - NCT07208240RecruitingPhase 1/Phase 2
PSMA-targeted radiation before prostate removal for advanced cancer
This trial tests giving a radioactive drug (PSMA-targeted) before surgery for prostate cancer that has spread locally but not to other parts of the body. The goal is to see if it helps lower the risk of the cancer coming back.
Petah TikvaAges 18 years+ - NCT07179757Recruiting
Vulvovaginal cancer treatment study
This study looks at how well treatments like radiation, chemotherapy, or surgery work for people with vulvar or vaginal cancer, and how they affect quality of life. It includes patients treated between 2019 and 2023.
Mumbai, MaharashtraAges Any age - NCT06549907Recruiting
Study of double immunotherapy plus anti-angiogenic therapy
This trial studies people with certain types of colorectal or other solid tumors that did not respond to a single immunotherapy drug. It tests whether adding a second immune checkpoint blocker and an anti-angiogenic drug can help control the cancer.
Beijing, Beijing MunicipalityAges 18 years+ - NCT05699811RecruitingPhase 1/Phase 2
Test of special immune-support cells for solid tumors
This study tests lab-made mesenchymal stromal cells that release interferon alpha (IFNα) for people with locally advanced or metastatic solid cancers. It’s designed to see if this treatment can help when standard treatments have failed or don’t have guideline options.
BeijingAges 18–75 - NCT06574620Recruiting
Studying tumor DNA and proteins in pancreatic cancer
This study is looking at genetic material and proteins from pancreatic tumors to understand how the cancer responds to treatment. It aims to help doctors choose the best therapies for patients with certain types of pancreatic cancer that can be removed surgically or that have not spread to other organs.
Vancouver, British ColumbiaAges 18 years+ - NCT06364371Recruiting
Predicting rectal cancer treatment response using multi-omics
This trial is testing a new way to predict how well your rectal cancer will respond to treatments given before surgery. It uses advanced tests (like looking at genes and other markers) to tailor your care.
Guangzhou, GuangdongAges 18–80 - NCT05759546RecruitingPhase 2
Test a PARP and CDK4/6 medicine plus hormone therapy
This Phase 2 study tests whether combining a PARP inhibitor with a CDK4/6 inhibitor and hormone (endocrine) therapy can help people with advanced HR-positive, HER2-negative breast cancer. It’s for certain patients who have not yet had chemotherapy or targeted therapy for metastatic disease.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT05841472RecruitingPhase 2
Camrelizumab plus chemo for advanced lung cancer without EGFR or ALK
This Phase 2 trial tests whether the immunotherapy drug camrelizumab, combined with pemetrexed and carboplatin, can work better as first treatment for advanced lung cancer that has no EGFR or ALK gene changes. You may be able to join if you have measurable disease, good enough organ function, and meet other safety rules for immune treatment.
AnamAges 19–80 - NCT06717880RecruitingPhase 1
Combination therapy for advanced colorectal cancer
This trial tests a new drug (IBI363) combined with either bevacizumab or furuitinib for people with advanced colorectal cancer that has worsened after standard treatments. It aims to find a more effective option for those who have limited alternatives.
Wuhan, HubeiAges 18–75 - NCT06001255RecruitingPhase 2
Testing HS-20093 for advanced prostate and other solid cancers
This trial is testing a new drug called HS-20093 for people with advanced prostate cancer or other solid tumors that have spread and stopped responding to standard treatments. The drug targets a protein on cancer cells to try to stop cancer growth.
BeijingAges 18 years+ - NCT07193862RecruitingEarly Phase 1
Testing a tiny device to find best treatments for liver tumors
This study tests a tiny device that is placed in your liver tumor during surgery. It checks how well different chemotherapy drugs work on your specific cancer, which may help your doctor choose the best treatment for you.
Lake Success, New YorkAges 18 years+ - NCT06391190RecruitingPhase 1/Phase 2
Chemoradiation plus immunotherapy for advanced cervical cancer
This trial tests combining standard chemoradiation with a PD-1 inhibitor (a drug that helps your immune system fight cancer) for advanced cervical cancer that hasn't been treated yet. The goal is to see if this combination works better than standard treatment alone.
ShanghaiAges 18–75 - NCT07040228RecruitingPhase 1/Phase 2
Study of regorafenib, toripalimab, and chemo for advanced pancreatic cancer
This trial tests a combination of three drugs (regorafenib, toripalimab, and albumin-bound paclitaxel) as a third-line treatment for advanced pancreatic cancer that has progressed after two prior therapies. The goal is to see if this combination can help shrink tumors or slow the cancer's growth.
Shenzhen, GuangdongAges 18–80 - NCT07340424RecruitingEarly Phase 1
Study of 225Ac-TR2205 for triple-negative breast cancer
This trial tests a new radioactive drug called 225Ac-TR2205 for people with triple-negative breast cancer that has spread. The goal is to see if it is safe and tolerable. It may be an option if you have tried at least two other treatments, including one for metastatic disease.
Jinan, ShandongAges 18 years+ - NCT04205968RecruitingPhase 2
Testing ramucirumab with chemo for advanced small bowel cancer
This trial studies whether adding ramucirumab to chemotherapy (either paclitaxel or FOLFIRI) works better for advanced small bowel adenocarcinoma that has already been treated with certain prior medicines. It may help shrink tumors or slow cancer growth in people whose cancer has progressed.
Anchorage, AlaskaAges 18 years+ - NCT07048457RecruitingPhase 2
Surgery for metastatic bladder cancer after initial treatment
This trial tests whether removing the primary bladder tumor and any remaining metastatic spots after initial medication (enfortumab-vedotin) improves outcomes for people with a limited number of metastases (5 or fewer). It is for those whose cancer has responded or stabilized on treatment.
New Haven, ConnecticutAges 18 years+ - NCT07646626RecruitingPhase 2
New antibody drugs for advanced HER2-positive cancers
This trial tests two new antibody drugs (SSGJ-705 and SSGJ-612), alone or combined with chemotherapy, in patients with advanced cancers that have a protein called HER2. The study aims to see if this combination can shrink tumors and help patients live longer.
Hangzhou, ZhejiangAges 18–75 - NCT07172282RecruitingEarly Phase 1
Immunotherapy for colorectal cancer liver metastases
This trial tests a new way to deliver immunotherapy directly into the liver for people with colorectal cancer that has spread only to the liver. The goal is to see if this approach can shrink tumors before surgery, and it may be an option if you've already had standard chemotherapy.
Lake Success, New YorkAges 18 years+ - NCT06128551RecruitingPhase 1/Phase 2
Testing two targeted drugs for KRAS G12C advanced cancer
This study tests two oral medicines (elironrasib and daraxonrasib) given alone or together to see if they can shrink tumors or slow down cancer growth in people with advanced solid tumors that have a KRAS G12C mutation. It is for people who have already tried other treatments.
Duarte, CaliforniaAges 18 years+ - NCT06662786RecruitingPhase 3
Amivantamab plus chemo vs. standard chemo for left-sided colorectal cancer
This trial compares a new combination (amivantamab plus chemotherapy) with the standard treatment (cetuximab plus chemotherapy) as the first therapy for people with left-sided colorectal cancer that has spread. The goal is to see which approach works better when the tumor has no mutations in the KRAS, NRAS, or BRAF genes.
Gilbert, ArizonaAges 18 years+
Hear when a new Colorectal Cancer (Locally Advanced or Metastatic) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for colorectal cancer (locally advanced or metastatic)?
- Yes. Clin2 currently lists 5,557 recruiting colorectal cancer (locally advanced or metastatic) studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a colorectal cancer (locally advanced or metastatic) trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a colorectal cancer (locally advanced or metastatic) trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
- Locally Advanced or Metastatic Breast Cancer
- Locally Advanced or Metastatic Non-small Cell Lung Cancer
- Locally Advanced Colorectal Cancer
- Lung Cancer (Locally Advanced or Metastatic)
- Liver Cancer (Locally Advanced or Metastatic)
- Metastatic Colorectal Cancer
- Locally Advanced Rectal Cancer
- Metastatic Colorectal Cancer (CRC)
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.